Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) b
NEW ORLEANS, March 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securitie
New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) be
SAN FRANCISCO, March 06, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therap
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
11:30am, Friday, 06'th Mar 2026
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporat
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
07:36pm, Thursday, 05'th Mar 2026
NEW YORK, March 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between Octo
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
03:42pm, Thursday, 05'th Mar 2026
Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps" SAN FRANCISCO, March 5, 2026 /PRNewswire/ -- National shareholder r
LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
09:30am, Thursday, 05'th Mar 2026
CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT
04:40am, Thursday, 05'th Mar 2026
LOS ANGELES, March 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept " or "the Company") (NASDAQ: CORT ) for vio
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
03:37am, Thursday, 05'th Mar 2026
LOS ANGELES, March 5, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated
NEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a secu
